CSIMarket
 
Surrozen Inc   (NASDAQ: SRZN)
Other Ticker:  
 
 
Price: $10.4100 $-0.69 -6.216%
Day's High: $11.65 Week Perf: -4.58 %
Day's Low: $ 10.28 30 Day Perf: -19.61 %
Volume (M): 16 52 Wk High: $ 18.17
Volume (M$): $ 166 52 Wk Avg: $10.51
Open: $11.55 52 Wk Low: $6.00



 Market Capitalization (Millions $) 34
 Shares Outstanding (Millions) 3
 Employees 27
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Surrozen Inc
Surrozen Inc. is a biotechnology company headquartered in San Francisco, California. It was founded in 2016 and is focused on developing novel therapeutics to regenerate damaged tissues and organs. Surrozen utilizes its proprietary technology platform to discover and develop drugs that target the Wnt signaling pathway, which plays a critical role in tissue repair and regeneration.

The company's therapeutics aim to activate the body's natural regenerative processes by stimulating specific cell types to enhance tissue healing. Surrozen's innovative approach holds potential for treating a wide range of diseases and injuries, including those affecting the liver, lung, and gastrointestinal system.

Surrozen has garnered significant attention and investment from prominent pharmaceutical companies and venture capital firms due to the promising potential of its technology. By leveraging advancements in stem cell biology and regenerative medicine, Surrozen seeks to revolutionize the treatment of various debilitating conditions and improve patient outcomes.

While still in the early stages of development, Surrozen has a strong team of scientists and industry experts dedicated to advancing its pipeline of regenerative therapeutics. The company's ultimate goal is to translate cutting-edge research into transformative therapies that have a profound impact on patients suffering from chronic or acute tissue damage.


   Company Address: 171 Oyster Point Blvd South San Francisco 94080 CA
   Company Phone Number: 489-9000    Stock Exchange / Ticker: NASDAQ SRZN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALGS        21.98% 
AMGN        1.32% 
BCRX        14.44% 
MRNA   -10.81%    
ALNY        0.6% 
ARWR        8% 
• View Complete Report
   



Clinical Study

A New Dawn in Idiopathic Pulmonary Fibrosis Surrozen and TCGFB Forge Pathway to Transformative Treatments

Published Mon, Nov 4 2024 1:31 PM UTC

In an exciting development for the field of respiratory diseases, Surrozen Inc. and TCGFB, Inc. have announced a strategic research collaboration aimed at developing transformative therapies for idiopathic pulmonary fibrosis (IPF). This partnership is poised to harness the power of TGF- antibodies, a promising avenue in the fight against this debilitating disease.Idiopathic ...

Clinical Study

Revolutionizing Tissue Regeneration Surrozens SWEETS Platform Enhances Wnt Signaling for Therapeutic Advancements...

Published Wed, Jun 12 2024 12:31 PM UTC

Enhancing Wnt Signaling: Surrozen s SWEETS Platform Shows Potential in Groundbreaking Study In a recent publication in eLife, Surrozen, a biotechnology company, has unveiled its proprietary SWEETS (Selective Wnt Enhancer Evolved from Targeted Secretion) platform. This innovative technology demonstrates the potential to revolutionize targeted protein degradation, specificall...

Clinical Study

Surrozen Unveils Promising Preliminary Results from Phase 1a Study of SZN-043 in Liver Cirrhosis Patients at EASL 202...

Published Mon, Jun 10 2024 12:30 PM UTC

At the prestigious 2024 European Association for the Study of the Liver (EASL) conference held in Milan, Surrozen Inc., a front-runner in biopharmaceutical innovation, presented groundbreaking preliminary results from its Phase 1a clinical study of SZN-043. This investigational drug is specifically aimed at addressing unmet medical needs in patients with liver cirrhosis, a c...

Clinical Study

Advancements in SZN-043: A Potential Breakthrough for Severe Alcohol-Associated Hepatitis

Published Tue, Jun 4 2024 12:30 PM UTC

Alcohol-Associated Hepatitis (AAH) is a life-threatening condition affecting individuals who consume excessive amounts of alcohol. It is characterized by inflammation and damage to the liver, leading to liver failure in severe cases. Currently, there is a pressing need for novel and effective treatments to address this condition. In this article, we will delve into recent ad...

Product Service News

Potential of Antibody-Based Wnt Mimetics Unveiled in Addressing Cornea Endothelial Dystrophies and Dry Eye Disease: Insights from Surrozen's Data showcased at ARVO 2024

Published Thu, May 9 2024 12:31 PM UTC

Abstract:The Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting witnessed groundbreaking presentations by Surrozen, shedding light on the incredible potential of antibody-based Wnt mimetics in the treatment of cornea endothelial dystrophies (CEDs) and dry eye disease (DED). Data presented at the conference underscored the efficacy and promise of this...







Surrozen Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com